Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aneuploidy in Cancer, Lessons from Acute Lymphoblastic Leukemia

  • Molina, Oscar|||0000-0001-7585-4519
  • Abad, Maria Alba|||0000-0002-8816-1524
  • Sole, F.|||0000-0002-3251-2161
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Aneuploidy, the gain or loss of chromosomes in a cell, is a hallmark of cancer. Although our understanding of the contribution of aneuploidy to cancer initiation and progression is incomplete, significant progress has been made in uncovering the cellular consequences of aneuploidy and how aneuploid cancer cells self-adapt to promote tumorigenesis. Aneuploidy is physiologically associated with significant cellular stress but, paradoxically, it favors tumor progression. Although more common in solid tumors, different forms of aneuploidy represent the initiating oncogenic lesion in patients with B cell acute lymphoblastic leukemia (B-ALL), making B-ALL an excellent model for studying the role of aneuploidy in tumorigenesis. We review the molecular mechanisms underlying aneuploidy and discuss its contributions to B-ALL initiation and progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms

  • Liquori, Alessandro|||0000-0002-4842-5986
  • Lesende, Iván
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Avetisyan, Gayane
  • Ibáñez, Mariam
  • González-Romero, Elisa
  • Boluda-Navarro, Mireia
  • Morote-Faubel, Mireya
  • Garcia-Ruiz, Cristian|||0000-0003-2914-7914
  • Martinez-Valiente, Cristina
  • Santiago-Balsera, Marta
  • Gomez-Seguí, Inés
  • Sanjuan-Pla, Alejandra
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Sanz, Guillermo|||0000-0002-2767-8191
  • Sole, F.|||0000-0002-3251-2161
  • Such, Esperanza|||0000-0001-6892-403X
  • Cervera, José|||0000-0001-8252-1106
Chromosomal abnormalities and somatic mutations are found in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in around 50-80% of cases. The identification of these alterations is important for the accurate diagnosis and prognostic classification of these patients. Often, an apparently normal or failed karyotype might lead to an inadequate estimation of the prognostic risk, and several strategies should be combined to solve these cases. The aim of this study was to introduce a novel next-generation sequencing (NGS)-based strategy for the simultaneous detection of all the clinically relevant genetic alterations associated with these disorders. We validated this approach on a large cohort of patients by comparing our findings with those obtained with standard-of-care methods (i.e., karyotype and SNP-arrays). We show that our platform represents a significant improvement on current strategies in defining diagnosis and risk stratification of patients with MDS and myeloid-related disorders. Myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms are clonal disorders that share most of their cytogenetic and molecular alterations. Despite the increased knowledge of the prognostic importance of genetics in these malignancies, next-generation sequencing (NGS) has not been incorporated into clinical practice in a validated manner, and the conventional karyotype remains mandatory in the evaluation of suspected cases. However, non-informative cytogenetics might lead to an inadequate estimation of the prognostic risk. Here, we present a novel targeted NGS-based assay for the simultaneous detection of all the clinically relevant genetic alterations associated with these disorders. We validated this platform in a large cohort of patients by performing a one-to-one comparison with the lesions from karyotype and single-nucleotide polymorphism (SNP) arrays. Our strategy demonstrated an approximately 97% concordance with standard clinical assays, showing sensitivity at least equivalent to that of SNP arrays and higher than that of conventional cytogenetics. In addition, this NGS assay was able to identify both copy-neutral loss of heterozygosity events distributed genome-wide and copy number alterations, as well as somatic mutations within significant driver genes. In summary, we show a novel NGS platform that represents a significant improvement to current strategies in defining diagnosis and risk stratification of patients with MDS and myeloid-related disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms

  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Acha, Pamela|||0000-0002-4528-1219
  • Sole, F.|||0000-0002-3251-2161
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (~90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q

  • Ademà, Vera|||0000-0001-6051-4378
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Walter, Wencke
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Hutter, Stephan|||0000-0003-2432-8898
  • La Framboise, Thomas
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Meggendorfer, Manja
  • Radivoyevitch, Tomas
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Pellagatti, Andrea
  • Haferlach, Claudia
  • Boultwood, Jacqueline|||0000-0002-4330-2928
  • Kern, Wolfgang|||0000-0002-6452-2874
  • Visconte, Valeria|||0000-0002-2993-1509
  • Sekeres, Mikkael|||0000-0003-2009-6524
  • Barnard, John|||0000-0003-2403-8268
  • Haferlach, T.|||0000-0003-0196-2837
  • Sole, F.|||0000-0002-3251-2161
  • Maciejewski, Jaroslaw|||0000-0002-6837-4346
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified. Methods: Here, we explored mutations, gene expression and clinical phenotypes of 388 del(5q) vs. 841 diploid cases with MN [82% myelodysplastic syndromes (MDS)]. Findings: Del(5q) resulted as founder (better prognosis) or secondary hit (preceded by TP53 mutations). Using Bayesian prediction analyses on 57 HI marker genes we established the minimal del(5q) gene signature that distinguishes del(5q) from diploid cases. Clusters of diploid cases mimicking the del(5q) signature support the overall importance of del(5q) genes in the pathogenesis of MDS in general. Sub-clusters within del(5q) patients pointed towards the inherent intrapatient heterogeneity of HI genes. Interpretation: The underlying clonal expansion drive results from a balance between the "HI-driver" genes (e.g., CSNK1A1, CTNNA1, TCERG1) and the proapoptotic "HI-anti-drivers" (e.g., RPS14, PURA, SIL1). The residual essential clonal expansion drive allows for selection of accelerator mutations such as TP53 (denominating poor) and CSNK1A1 mutations (with a better prognosis) which overcome pro-apoptotic genes (e.g., p21, BAD, BAX), resulting in a clonal expansion. In summary, we describe the complete picture of del(5q) MN identifying the crucial genes, gene clusters and clonal hierarchy dictating the clinical course of del(5q) patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

  • Calvete, Oriol|||0000-0002-2623-2876
  • Mestre, Julia|||0000-0002-4809-3897
  • Jerez, Andrés|||0000-0002-2079-6638
  • Sole, F|||0000-0002-3251-2161
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib, Implications for Therapy Resistance

  • Bistué Rovira, Àngel|||0009-0000-9067-7557
  • G. Rico, Laura|||0000-0001-9867-4393
  • Bardina, Jorge
  • Junca, Jordi|||0000-0003-0142-772X
  • Granada, Isabel|||0000-0002-4275-0104
  • Bradford, Jolene A.
  • Ward, Michael D.
  • Salvia, Roser|||0000-0002-2118-9231
  • Sole, F.|||0000-0002-3251-2161
  • Petriz, Jordi|||0000-0003-1085-0511
Leukemic stem cells (LSCs) possess similar characteristics to normal hematopoietic stem cells, including self-renewal capacity, quiescence, ability to initiate leukemia, and drug resistance. These cells play a significant role in leukemia relapse, persisting even after apparent remission. LSCs were first described in 1994 by Lapidot et al. Although they have been extensively studied in acute leukemia, more LSC research is still needed in chronic lymphocytic leukemia (CLL) to understand if reduced apoptosis in mature cells should still be considered as the major cause of this disease. Here, we provide new evidence suggesting the existence of stem-like cell populations in CLL, which may help to understand the disease as well as to develop effective treatments. In this study, we identified a potential leukemic stem cell subpopulation using the tetraploid CLL cell line I83. This subpopulation is characterized by diploid cells that were capable of generating the I83 tetraploid population. Furthermore, we adapted a novel flow cytometry analysis protocol to detect CLL subpopulations with stem cell properties in peripheral blood samples and primary cultures from CLL patients. These cells were identified by their co-expression of CD19 and CD5, characteristic markers of CLL cells. As previously described, increased alkaline phosphatase (ALP) activity is indicative of stemness and pluripotency. Moreover, we used this method to investigate the potential synergistic effect of curcumin in combination with fludarabine and ibrutinib to deplete this subpopulation. Our results confirmed the effectiveness of this ALP-based analysis protocol in detecting and monitoring leukemic stem-like cells in CLL. This analysis also identified limitations in eradicating these populations using in vitro testing. Furthermore, our findings demonstrated that curcumin significantly enhanced the effects of fludarabine and ibrutinib on the leukemic fraction, exhibiting synergistic effects (combination drug index, CDI 0.97 and 0.37, respectively). Our results lend support to the existence of potential stem-like populations in CLL cell lines, and to the idea that curcumin could serve as an effective adjuvant in therapies aimed at eliminating these populations and improving treatment efficacy.